A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism
A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Un...
Gespeichert in:
Veröffentlicht in: | Anesthesiology (Philadelphia) 2003-04, Vol.98 (4), p.906-911 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 911 |
---|---|
container_issue | 4 |
container_start_page | 906 |
container_title | Anesthesiology (Philadelphia) |
container_volume | 98 |
creator | JOOSTE, Edmund KLAFTER, Farrah HIRSHMAN, Carol A EMALA, Charles W |
description | A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clinically. Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction.
Competitive radioligand binding determined the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors.
Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clinically relevant concentrations. Fifty percent inhibitory concentrations (mean +/- SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10 +/- 1.5 microm (n = 6); M3 muscarinic receptor, 77.9 +/- 11 microm (n = 8). Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clinically achieved concentrations for these relaxants.
Rapacuronium in clinically significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors. A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction. |
doi_str_mv | 10.1097/00000542-200304000-00017 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmed_primary_12657852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12657852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c286t-646796e10eb001c0703f7703a08a11cdd1ae3aff270a9e7e5557c378226abc163</originalsourceid><addsrcrecordid>eNpFkEtLAzEUhYMotlb_gmTjMprH5FF3pfiCipu6Hu5kEhtpZoaks_Dfm9qqgeRywjmXez-EMKO3jM71Hd0fWXHCKRW0KoKUy_QJmjLJDWFMy1M0LX-CCMr5BF3k_FmklsKcownjSmoj-RStFzg6u4Eu5Ih9n3CCAeyY-i6MkYSuHa1rcVO03fR5gBzv8SvHccwWUuiCxclZN-xKErodfPT7RpfozMM2u6tjnaH3x4f18pms3p5elosVsdyoHVGV0nPlGHVNGd5STYXX5QFqgDHbtgycAO-5pjB32kkptRXacK6gsUyJGTKHvjb1OSfn6yGFCOmrZrTeg6p_QdV_oOofUCV6fYgOYxNd-x88kimGm6MByqpbn6CzIf_7Kl0gV0Z8A-K1cIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>JOOSTE, Edmund ; KLAFTER, Farrah ; HIRSHMAN, Carol A ; EMALA, Charles W</creator><creatorcontrib>JOOSTE, Edmund ; KLAFTER, Farrah ; HIRSHMAN, Carol A ; EMALA, Charles W</creatorcontrib><description>A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clinically. Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction.
Competitive radioligand binding determined the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors.
Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clinically relevant concentrations. Fifty percent inhibitory concentrations (mean +/- SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10 +/- 1.5 microm (n = 6); M3 muscarinic receptor, 77.9 +/- 11 microm (n = 8). Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clinically achieved concentrations for these relaxants.
Rapacuronium in clinically significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors. A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.</description><identifier>ISSN: 0003-3022</identifier><identifier>EISSN: 1528-1175</identifier><identifier>DOI: 10.1097/00000542-200304000-00017</identifier><identifier>PMID: 12657852</identifier><identifier>CODEN: ANESAV</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Animals ; Atracurium - pharmacology ; Binding, Competitive - drug effects ; Biological and medical sciences ; Bronchial Spasm - chemically induced ; Bronchial Spasm - physiopathology ; Cell Membrane - drug effects ; CHO Cells ; Cricetinae ; Diamines - pharmacology ; Drug toxicity and drugs side effects treatment ; Indicators and Reagents ; Medical sciences ; Muscarinic Antagonists ; Neuromuscular Nondepolarizing Agents - toxicity ; Pharmacology. Drug treatments ; Piperidines - pharmacology ; Quinuclidinyl Benzilate - pharmacology ; Radioligand Assay ; Receptor, Muscarinic M2 ; Receptor, Muscarinic M3 ; Receptors, Muscarinic - drug effects ; Toxicity: respiratory system, ent, stomatology ; Vecuronium Bromide - analogs & derivatives ; Vecuronium Bromide - pharmacology ; Vecuronium Bromide - toxicity</subject><ispartof>Anesthesiology (Philadelphia), 2003-04, Vol.98 (4), p.906-911</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14711748$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12657852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JOOSTE, Edmund</creatorcontrib><creatorcontrib>KLAFTER, Farrah</creatorcontrib><creatorcontrib>HIRSHMAN, Carol A</creatorcontrib><creatorcontrib>EMALA, Charles W</creatorcontrib><title>A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism</title><title>Anesthesiology (Philadelphia)</title><addtitle>Anesthesiology</addtitle><description>A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clinically. Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction.
Competitive radioligand binding determined the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors.
Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clinically relevant concentrations. Fifty percent inhibitory concentrations (mean +/- SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10 +/- 1.5 microm (n = 6); M3 muscarinic receptor, 77.9 +/- 11 microm (n = 8). Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clinically achieved concentrations for these relaxants.
Rapacuronium in clinically significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors. A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.</description><subject>Animals</subject><subject>Atracurium - pharmacology</subject><subject>Binding, Competitive - drug effects</subject><subject>Biological and medical sciences</subject><subject>Bronchial Spasm - chemically induced</subject><subject>Bronchial Spasm - physiopathology</subject><subject>Cell Membrane - drug effects</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Diamines - pharmacology</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Indicators and Reagents</subject><subject>Medical sciences</subject><subject>Muscarinic Antagonists</subject><subject>Neuromuscular Nondepolarizing Agents - toxicity</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - pharmacology</subject><subject>Quinuclidinyl Benzilate - pharmacology</subject><subject>Radioligand Assay</subject><subject>Receptor, Muscarinic M2</subject><subject>Receptor, Muscarinic M3</subject><subject>Receptors, Muscarinic - drug effects</subject><subject>Toxicity: respiratory system, ent, stomatology</subject><subject>Vecuronium Bromide - analogs & derivatives</subject><subject>Vecuronium Bromide - pharmacology</subject><subject>Vecuronium Bromide - toxicity</subject><issn>0003-3022</issn><issn>1528-1175</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLAzEUhYMotlb_gmTjMprH5FF3pfiCipu6Hu5kEhtpZoaks_Dfm9qqgeRywjmXez-EMKO3jM71Hd0fWXHCKRW0KoKUy_QJmjLJDWFMy1M0LX-CCMr5BF3k_FmklsKcownjSmoj-RStFzg6u4Eu5Ih9n3CCAeyY-i6MkYSuHa1rcVO03fR5gBzv8SvHccwWUuiCxclZN-xKErodfPT7RpfozMM2u6tjnaH3x4f18pms3p5elosVsdyoHVGV0nPlGHVNGd5STYXX5QFqgDHbtgycAO-5pjB32kkptRXacK6gsUyJGTKHvjb1OSfn6yGFCOmrZrTeg6p_QdV_oOofUCV6fYgOYxNd-x88kimGm6MByqpbn6CzIf_7Kl0gV0Z8A-K1cIg</recordid><startdate>20030401</startdate><enddate>20030401</enddate><creator>JOOSTE, Edmund</creator><creator>KLAFTER, Farrah</creator><creator>HIRSHMAN, Carol A</creator><creator>EMALA, Charles W</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20030401</creationdate><title>A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism</title><author>JOOSTE, Edmund ; KLAFTER, Farrah ; HIRSHMAN, Carol A ; EMALA, Charles W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c286t-646796e10eb001c0703f7703a08a11cdd1ae3aff270a9e7e5557c378226abc163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Atracurium - pharmacology</topic><topic>Binding, Competitive - drug effects</topic><topic>Biological and medical sciences</topic><topic>Bronchial Spasm - chemically induced</topic><topic>Bronchial Spasm - physiopathology</topic><topic>Cell Membrane - drug effects</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Diamines - pharmacology</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Indicators and Reagents</topic><topic>Medical sciences</topic><topic>Muscarinic Antagonists</topic><topic>Neuromuscular Nondepolarizing Agents - toxicity</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - pharmacology</topic><topic>Quinuclidinyl Benzilate - pharmacology</topic><topic>Radioligand Assay</topic><topic>Receptor, Muscarinic M2</topic><topic>Receptor, Muscarinic M3</topic><topic>Receptors, Muscarinic - drug effects</topic><topic>Toxicity: respiratory system, ent, stomatology</topic><topic>Vecuronium Bromide - analogs & derivatives</topic><topic>Vecuronium Bromide - pharmacology</topic><topic>Vecuronium Bromide - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JOOSTE, Edmund</creatorcontrib><creatorcontrib>KLAFTER, Farrah</creatorcontrib><creatorcontrib>HIRSHMAN, Carol A</creatorcontrib><creatorcontrib>EMALA, Charles W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Anesthesiology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JOOSTE, Edmund</au><au>KLAFTER, Farrah</au><au>HIRSHMAN, Carol A</au><au>EMALA, Charles W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism</atitle><jtitle>Anesthesiology (Philadelphia)</jtitle><addtitle>Anesthesiology</addtitle><date>2003-04-01</date><risdate>2003</risdate><volume>98</volume><issue>4</issue><spage>906</spage><epage>911</epage><pages>906-911</pages><issn>0003-3022</issn><eissn>1528-1175</eissn><coden>ANESAV</coden><abstract>A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clinically. Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction.
Competitive radioligand binding determined the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors.
Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clinically relevant concentrations. Fifty percent inhibitory concentrations (mean +/- SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10 +/- 1.5 microm (n = 6); M3 muscarinic receptor, 77.9 +/- 11 microm (n = 8). Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clinically achieved concentrations for these relaxants.
Rapacuronium in clinically significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors. A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>12657852</pmid><doi>10.1097/00000542-200304000-00017</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-3022 |
ispartof | Anesthesiology (Philadelphia), 2003-04, Vol.98 (4), p.906-911 |
issn | 0003-3022 1528-1175 |
language | eng |
recordid | cdi_pubmed_primary_12657852 |
source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
subjects | Animals Atracurium - pharmacology Binding, Competitive - drug effects Biological and medical sciences Bronchial Spasm - chemically induced Bronchial Spasm - physiopathology Cell Membrane - drug effects CHO Cells Cricetinae Diamines - pharmacology Drug toxicity and drugs side effects treatment Indicators and Reagents Medical sciences Muscarinic Antagonists Neuromuscular Nondepolarizing Agents - toxicity Pharmacology. Drug treatments Piperidines - pharmacology Quinuclidinyl Benzilate - pharmacology Radioligand Assay Receptor, Muscarinic M2 Receptor, Muscarinic M3 Receptors, Muscarinic - drug effects Toxicity: respiratory system, ent, stomatology Vecuronium Bromide - analogs & derivatives Vecuronium Bromide - pharmacology Vecuronium Bromide - toxicity |
title | A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A29%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20mechanism%20for%20rapacuronium-induced%20bronchospasm:%20M2%20muscarinic%20receptor%20antagonism&rft.jtitle=Anesthesiology%20(Philadelphia)&rft.au=JOOSTE,%20Edmund&rft.date=2003-04-01&rft.volume=98&rft.issue=4&rft.spage=906&rft.epage=911&rft.pages=906-911&rft.issn=0003-3022&rft.eissn=1528-1175&rft.coden=ANESAV&rft_id=info:doi/10.1097/00000542-200304000-00017&rft_dat=%3Cpubmed_cross%3E12657852%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12657852&rfr_iscdi=true |